1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow OKN 007: new trials by email Literature Review of OKN 007 trials Research Report on OKN 007
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants OKN-007 - Glioblastoma, Astrocytoma | Phase 1 / Phase 2 | Withdrawn | Oblato, Inc. | 2022-08-01 | 2022-10-07 | |
| Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma OKN-007, Temozolomide (TMZ) - Recurrent Malignant Glioma, Brain Glioblastoma | Phase 2 | Completed | Oblato, Inc. | 57 | 2020-06-12 | 2025-08-12 |
Glioma (2) · Astrocytoma (1) · Glioblastoma (1) · Oligodendroglioma (1)
Oblato, Inc. (2)
United States (1)